What the FDA labels say about taking them together
Heparin and hydroxychloroquine
Heparin's FDA label (Heparin Sodium) of April 30, 2026 names hydroxychloroquine in its drug interactions section; the hydroxychloroquine labels PlainMeds reads (2) do not name heparin. The heparin label: “Drugs such as NSAIDS, dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIv/IIa antagonists, and others that interfere with platelet-aggregation reactions may induce bleeding and …”
Check it at the source: the heparin FDA label on DailyMed (effective November 28, 2025, Fresenius Kabi USA, LLC); the hydroxychloroquine FDA label on DailyMed (effective October 8, 2024, ANI Pharmaceuticals, Inc.).
What does the heparin label say about hydroxychloroquine?
Heparin Sodium label (Fresenius Kabi USA, LLC, April 30, 2026), drug interactionsDrugs such as NSAIDS (including salicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
Heparin Sodium label (Hospira, Inc., May 12, 2026), drug interactionsDrugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
Source: FDA drug label (Heparin Sodium, NDA017029), Fresenius Kabi USA, LLC, effective April 30, 2026 (SPL set 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5), via openFDA
Source: FDA drug label (Heparin Sodium, NDA018916), Hospira, Inc., effective May 12, 2026 (SPL set 0413f511-6b34-4c15-e48b-3fad08baacbe), via openFDA
Source: FDA drug label (Heparin Sodium In Sodium Chloride, NDA018609), Baxter Healthcare Corporation, effective January 3, 2022 (SPL set 0d929726-76c3-48fc-b4e7-fd06409f9fb3), via openFDA
Source: FDA drug label (Heparin Sodium), Fresenius Kabi USA, LLC, effective November 28, 2025 (SPL set d55b4a63-0c04-4874-b74f-9e9b9e8b008c), via openFDA; the full label on DailyMed
What does the hydroxychloroquine label say about heparin?
Hydroxychloroquine's label (effective October 8, 2024) and its 1 other brand-application label do not name heparin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (SOVUNA), ANI Pharmaceuticals, Inc., effective October 8, 2024 (SPL set dd441154-b196-4d4c-bc56-2e37f345ef8d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Heparin | Hydroxychloroquine | |
|---|---|---|
| Labeled for | Blood clots (DVT and PE), Atrial fibrillation | Rheumatoid arthritis |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.18 per mL 5,000 unit/mL vial | $0.149 per tablet 200 mg tablet |
| Shortage now | In shortage | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once